InvestorsHub Logo
Followers 185
Posts 10548
Boards Moderated 0
Alias Born 11/23/2007

Re: None

Thursday, 10/12/2017 9:44:04 AM

Thursday, October 12, 2017 9:44:04 AM

Post# of 348

Merck announced after hours yesterday it will not be seeking to bring it's developmental drug Anacetrapib (CETP Inhibitor) to market.

Merck now has a clear cardiovascular drug candidate void in its pipeline & with MRK’s #Zetia, ESPR is the logical drug candidate 2 fill it.

Long ESPR
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ESPR News